<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34696334</PMID><DateCompleted><Year>2021</Year><Month>12</Month><Day>03</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1999-4915</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>10</Issue><PubDate><Year>2021</Year><Month>Sep</Month><Day>23</Day></PubDate></JournalIssue><Title>Viruses</Title><ISOAbbreviation>Viruses</ISOAbbreviation></Journal><ArticleTitle>The Cross-Talk between Thrombosis and Inflammatory Storm in Acute and Long-COVID-19: Therapeutic Targets and Clinical Cases.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1904</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/v13101904</ELocationID><Abstract><AbstractText>Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) commonly complicates with coagulopathy. A syndrome called Long-COVID-19 is emerging recently in COVID-19 survivors, characterized, in addition to the persistence of symptoms typical of the acute phase, by alterations in inflammatory and coagulation parameters due to endothelial damage. The related disseminated intravascular coagulation (DIC) can be associated with high death rates in COVID-19 patients. It is possible to find a prothrombotic state also in Long-COVID-19. Early administration of anticoagulants in COVID-19 was suggested in order to improve patient outcomes, although exact criteria for their application were not well-established. Low-molecular-weight heparin (LMWH) was commonly adopted for counteracting DIC and venous thromboembolism (VTE), due to its pharmacodynamics and anti-inflammatory properties. However, the efficacy of anticoagulant therapy for COVID-19-associated DIC is still a matter of debate. Thrombin and Factor Xa (FXa) are well-known components of the coagulation cascade. The FXa is known to strongly promote inflammation as the consequence of increased cytokine expression. Endothelial cells and mononuclear leucocytes release cytokines, growth factors, and adhesion molecules due to thrombin activation. On the other hand, cytokines can activate coagulation. The cross-talk between coagulation and inflammation is mediated via protease-activated receptors (PARs). These receptors might become potential targets to be considered for counteracting the clinical expressions of COVID-19. SARS-CoV-2 is effectively able to activate local and circulating coagulation factors, thus inducing the generation of disseminated coagula. LMWH may be considered as the new frontier in the treatment of COVID-19 and Long-COVID-19. Indeed, direct oral anticoagulants (DOACs) may be an alternative option for both early and later treatment of COVID-19 patients due to their ability to inhibit PARs. The aim of this report was to evaluate the role of anticoagulants-and DOACs in particular in COVID-19 and Long-COVID-19 patients. We report the case of a COVID-19 patient who, after administration of enoxaparin developed DIC secondary to virosis and positivity for platelet factor 4 (PF4) and a case of Long-COVID with high residual cardiovascular risk and persistence of blood chemistry of inflammation and procoagulative state.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Acanfora</LastName><ForeName>Domenico</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, San Francesco Hospital, Viale Europa 21, 82037 Telese Terme, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Acanfora</LastName><ForeName>Chiara</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, San Francesco Hospital, Viale Europa 21, 82037 Telese Terme, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, 67100 L'Aquila, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ciccone</LastName><ForeName>Marco Matteo</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Section of Cardiovascular Diseases, Department of Emergency and Organ Transplantation, School of Medicine, University of Bari, 70124 Bari, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scicchitano</LastName><ForeName>Pietro</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0003-0471-0053</Identifier><AffiliationInfo><Affiliation>Section of Cardiovascular Diseases, Department of Emergency and Organ Transplantation, School of Medicine, University of Bari, 70124 Bari, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bortone</LastName><ForeName>Alessandro Santo</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Division of Cardiac Surgery, Department of Emergency and Organ Transplantation, University of Bari, 70124 Bari, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Uguccioni</LastName><ForeName>Massimo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Cardiology Unit, San Camillo Hospital, 00152 Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Casucci</LastName><ForeName>Gerardo</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, San Francesco Hospital, Viale Europa 21, 82037 Telese Terme, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>09</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Viruses</MedlineTA><NlmUniqueID>101509722</NlmUniqueID><ISSNLinking>1999-4915</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D065427">Factor Xa Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006495">Heparin, Low-Molecular-Weight</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000925" MajorTopicYN="N">Anticoagulants</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001777" MajorTopicYN="N">Blood Coagulation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001778" MajorTopicYN="N">Blood Coagulation Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D042783" MajorTopicYN="N">Endothelial Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065427" MajorTopicYN="N">Factor Xa Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006495" MajorTopicYN="N">Heparin, Low-Molecular-Weight</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000472" MajorTopicYN="N">pathogenicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018746" MajorTopicYN="N">Systemic Inflammatory Response Syndrome</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013927" MajorTopicYN="N">Thrombosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="N">COVID-19 Drug Treatment</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">DOACs</Keyword><Keyword MajorTopicYN="N">LMWH</Keyword><Keyword MajorTopicYN="N">Long-COVID-19</Keyword><Keyword MajorTopicYN="N">PARs</Keyword><Keyword MajorTopicYN="N">anticoagulants</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>8</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>9</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>9</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>10</Month><Day>26</Day><Hour>1</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>10</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>12</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>9</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34696334</ArticleId><ArticleId IdType="pmc">PMC8540492</ArticleId><ArticleId IdType="doi">10.3390/v13101904</ArticleId><ArticleId IdType="pii">v13101904</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Zhang Y., Xiao M., Zhang S., Xia P., Cao W., Jiang W., Chen H., Ding X., Zhao H., Zhang H., et al. Coagulopathy and Antiphospholipid Antibodies in Patients with COVID-19. N. Engl. J. Med. 2020;382:e38. doi: 10.1056/NEJMc2007575.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2007575</ArticleId><ArticleId IdType="pmc">PMC7161262</ArticleId><ArticleId IdType="pubmed">32268022</ArticleId></ArticleIdList></Reference><Reference><Citation>Iba T., Watanabe E., Umemura Y., Wada T., Hayashida K., Kushimoto S., Wada H. Sepsis-associated disseminated intravascular coagulation and its differential diag-noses. J. Intensive Care. 2019;32:7&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6528221</ArticleId><ArticleId IdType="pubmed">31139417</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou F., Yu T., Du R., Fan G., Liu Y., Liu Z., Xiang J., Wang Y., Song B., Gu X., et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet. 2020;395:1054&#x2013;1062. doi: 10.1016/S0140-6736(20)30566-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30566-3</ArticleId><ArticleId IdType="pmc">PMC7270627</ArticleId><ArticleId IdType="pubmed">32171076</ArticleId></ArticleIdList></Reference><Reference><Citation>Wichmann D., Sperhake J.-P., L&#xfc;tgehetmann M., Steurer S., Edler C., Heinemann A., Heinrich F., Mushumba H., Kniep I., Schr&#xf6;der A.S., et al. Autopsy Findings and Venous Thromboembolism in Patients With COVID-19. Ann. Intern. Med. 2020;173:268&#x2013;277. doi: 10.7326/M20-2003.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M20-2003</ArticleId><ArticleId IdType="pmc">PMC7240772</ArticleId><ArticleId IdType="pubmed">32374815</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang N., Li D., Wang X., Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J. Thromb. Haemost. 2020;18:844&#x2013;847. doi: 10.1111/jth.14768.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.14768</ArticleId><ArticleId IdType="pmc">PMC7166509</ArticleId><ArticleId IdType="pubmed">32073213</ArticleId></ArticleIdList></Reference><Reference><Citation>Lillicrap D. Disseminated intravascular coagulation in patients with 2019-nCoV pneumonia. J. Thromb. Haemost. 2020;18:786&#x2013;787. doi: 10.1111/jth.14781.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.14781</ArticleId><ArticleId IdType="pmc">PMC7166410</ArticleId><ArticleId IdType="pubmed">32212240</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernard G.R., Vincent J.-L., Laterre P.-F., LaRosa S.P., Dhainaut J.-F., Lopez-Rodriguez A., Steingrub J.S., Garber G.E., Helterbrand J.D., Ely E.W., et al. Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis. N. Engl. J. Med. 2001;344:699&#x2013;709. doi: 10.1056/NEJM200103083441001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM200103083441001</ArticleId><ArticleId IdType="pubmed">11236773</ArticleId></ArticleIdList></Reference><Reference><Citation>Alaniz C. An Update on Activated Protein C (Xigris) In the Management of Sepsis. Pharm. Ther. 2010;35:504&#x2013;508.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2957744</ArticleId><ArticleId IdType="pubmed">20975809</ArticleId></ArticleIdList></Reference><Reference><Citation>Paranjpe I., Fuster V., Lala A., Russak A.J., Glicksberg B., Levin M.A., Charney A.W., Narula J., Fayad Z.A., Bagiella E., et al. Association of Treatment Dose Anticoagulation With In-Hospital Survival Among Hospitalized Patients With COVID-19. J. Am. Coll. Cardiol. 2020;76:122&#x2013;124. doi: 10.1016/j.jacc.2020.05.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2020.05.001</ArticleId><ArticleId IdType="pmc">PMC7202841</ArticleId><ArticleId IdType="pubmed">32387623</ArticleId></ArticleIdList></Reference><Reference><Citation>Jose R.J.P., Manuel A. COVID-19 cytokine storm: The interplay between inflammation and coagulation. Lancet Respir. Med. 2020;8:e46&#x2013;e47. doi: 10.1016/S2213-2600(20)30216-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(20)30216-2</ArticleId><ArticleId IdType="pmc">PMC7185942</ArticleId><ArticleId IdType="pubmed">32353251</ArticleId></ArticleIdList></Reference><Reference><Citation>Iba T., Levy J.H., Warkentin T.E., Thachil J., van der Poll T., Levi M. Diagnosis and management of sepsis-induced coagulopathy and disseminated in-travascular coagulation. J. Thromb. Haemost. 2019;11:1989&#x2013;1994. doi: 10.1111/jth.14578.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.14578</ArticleId><ArticleId IdType="pubmed">31410983</ArticleId></ArticleIdList></Reference><Reference><Citation>Iba T., Di Nisio M., Levy J.H., Kitamura N., Thachil J. New criteria for sepsis-induced coagulopathy (SIC) following the revised sepsis definition: A retrospective analysis of a nationwide survey. BMJ Open. 2017;7:e017046. doi: 10.1136/bmjopen-2017-017046.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2017-017046</ArticleId><ArticleId IdType="pmc">PMC5623518</ArticleId><ArticleId IdType="pubmed">28963294</ArticleId></ArticleIdList></Reference><Reference><Citation>Du R.-H., Liang L.-R., Yang C.-Q., Wang W., Cao T.-Z., Li M., Guo G.-Y., Du J., Zheng C.-L., Zhu Q., et al. Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: A prospective cohort study. Eur. Respir. J. 2020;55:2000524. doi: 10.1183/13993003.00524-2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.00524-2020</ArticleId><ArticleId IdType="pmc">PMC7144257</ArticleId><ArticleId IdType="pubmed">32269088</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang W.-H., Guan W.-J., Li C., Li Y.-M., Liang H.-R., Zhao Y., Liu X.-Q., Sang L., Chen R.-C., Tang C.-L., et al. Clinical characteristics and outcomes of hospitalised patients with COVID-19 treated in Hubei (epicentre) and outside Hubei (non-epicentre): A nationwide analysis of China. Eur. Respir. J. 2020;55:2000562. doi: 10.1183/13993003.00562-2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.00562-2020</ArticleId><ArticleId IdType="pmc">PMC7144336</ArticleId><ArticleId IdType="pubmed">32269086</ArticleId></ArticleIdList></Reference><Reference><Citation>Istituto Superiore di Sanit&#xe0; Caratteristiche dei Pazienti Deceduti Positivi a COVID-19 in Italia.  [(accessed on 1 July 2021)].  Available online:  www.epicentro.iss.it/coronavirus/bollettino/Report-COVID-2019_2_aprile_eng.pdf.</Citation></Reference><Reference><Citation>Casucci G., Acanfora D., Incalzi R.A. The Cross-Talk between Age, Hypertension and Inflammation in COVID-19 Patients: Therapeutic Targets. Drugs Aging. 2020;37:779&#x2013;785. doi: 10.1007/s40266-020-00808-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40266-020-00808-4</ArticleId><ArticleId IdType="pmc">PMC7575413</ArticleId><ArticleId IdType="pubmed">33084001</ArticleId></ArticleIdList></Reference><Reference><Citation>Li J.-Y., You Z., Wang Q., Zhou Z.-J., Qiu Y., Luo R., Ge X.-Y. The epidemic of 2019-novel-coronavirus (2019-nCoV) pneumonia and insights for emerging infectious diseases in the future. Microbes Infect. 2020;22:80&#x2013;85. doi: 10.1016/j.micinf.2020.02.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micinf.2020.02.002</ArticleId><ArticleId IdType="pmc">PMC7079563</ArticleId><ArticleId IdType="pubmed">32087334</ArticleId></ArticleIdList></Reference><Reference><Citation>Guan W.-J., Ni Z.-Y., Hu Y., Liang W.-H., Ou C.-Q., He J.-X., Liu L., Shan H., Lei C.-L., Hui D.S., et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N. Engl. J. Med. 2020;382:1708&#x2013;1720. doi: 10.1056/NEJMoa2002032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2002032</ArticleId><ArticleId IdType="pmc">PMC7092819</ArticleId><ArticleId IdType="pubmed">32109013</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang X., Yu Y., Xu J., Shu H., Xia J., Liu H., Wu Y., Zang L., Yu Z., Fang M., et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: A single-centered, retrospective, observational study. Lancet Respir. Med. 2020;8:475&#x2013;481. doi: 10.1016/S2213-2600(20)30079-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(20)30079-5</ArticleId><ArticleId IdType="pmc">PMC7102538</ArticleId><ArticleId IdType="pubmed">32105632</ArticleId></ArticleIdList></Reference><Reference><Citation>Franceschi C., Garagnani P., Parini P., Giuliani C., Santoro A. Inflammaging: A new immune&#x2013;metabolic viewpoint for age-related diseases. Nat. Rev. Endocrinol. 2018;14:576&#x2013;590. doi: 10.1038/s41574-018-0059-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41574-018-0059-4</ArticleId><ArticleId IdType="pubmed">30046148</ArticleId></ArticleIdList></Reference><Reference><Citation>Brook C.E., Boots M., Chandran K., Dobson A.P., Drosten C., Graham A.L., Grenfell B.T., M&#xfc;ller M.A., Ng M., Wang L.-F., et al. Accelerated viral dynamics in bat cell lines, with implications for zoonotic emergence. eLife. 2020;9:e48401. doi: 10.7554/eLife.48401.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.48401</ArticleId><ArticleId IdType="pmc">PMC7064339</ArticleId><ArticleId IdType="pubmed">32011232</ArticleId></ArticleIdList></Reference><Reference><Citation>He X., Li Z., Tang X., Zhang L., Wang L., He Y., Jin T., Yuan D. Age- and sex-related differences in body composition in healthy subjects aged 18 to 82 years. Medicine. 2018;97:e11152. doi: 10.1097/MD.0000000000011152.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000011152</ArticleId><ArticleId IdType="pmc">PMC6023800</ArticleId><ArticleId IdType="pubmed">29924020</ArticleId></ArticleIdList></Reference><Reference><Citation>Bourgonje A.R., Abdulle A.E., Timens W., Hillebrands J., Navis G.J., Gordijn S.J., Bolling M.C., Dijkstra G., Voors A.A., Osterhaus A.D.M.E., et al. Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19) J. Pathol. 2020;251:228&#x2013;248. doi: 10.1002/path.5471.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/path.5471</ArticleId><ArticleId IdType="pmc">PMC7276767</ArticleId><ArticleId IdType="pubmed">32418199</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang J., Zheng Y., Gou X., Pu K., Chen Z., Guo Q., Ji R., Wang H., Wang Y., Zhou Y. Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: A sys-tematic review and meta-analysis. Int. J. Infect. Dis. 2020;9712:91&#x2013;95. doi: 10.1016/j.ijid.2020.03.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2020.03.017</ArticleId><ArticleId IdType="pmc">PMC7194638</ArticleId><ArticleId IdType="pubmed">32173574</ArticleId></ArticleIdList></Reference><Reference><Citation>Varga Z., Flammer A.J., Steiger P., Haberecker M., Andermatt R., Zinkernagel A.S., Mehra M.R., Schuepbach R., Ruschitzka F., Moch H. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395:1417&#x2013;1418. doi: 10.1016/S0140-6736(20)30937-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30937-5</ArticleId><ArticleId IdType="pmc">PMC7172722</ArticleId><ArticleId IdType="pubmed">32325026</ArticleId></ArticleIdList></Reference><Reference><Citation>Bikdeli B., Madhavan M.V., Jimenez D., Chuich T., Dreyfus I., Driggin E., Der Nigoghossian C., Ageno W., Madjid M., Guo Y., et al. COVID-19 and thrombotic or thromboembolic disease: Implication for pre-vention, antithrombotic therapy, and follow-up. J. Am. Coll. Cardiol. 2020;75:2950&#x2013;2973. doi: 10.1016/j.jacc.2020.04.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2020.04.031</ArticleId><ArticleId IdType="pmc">PMC7164881</ArticleId><ArticleId IdType="pubmed">32311448</ArticleId></ArticleIdList></Reference><Reference><Citation>Poterucha T.J., Libby P., Goldhaber S.Z. More than an anticoagulant: Do heparins have direct anti-inflammatory effects? Thromb. Haemost. 2017;3:437&#x2013;444. doi: 10.1160/TH16-08-0620.</Citation><ArticleIdList><ArticleId IdType="doi">10.1160/TH16-08-0620</ArticleId><ArticleId IdType="pubmed">27975101</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang N., Bai H., Chen X., Gong J., Li D., Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J. Thromb. Haemost. 2020;18:1094&#x2013;1099. doi: 10.1111/jth.14817.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.14817</ArticleId><ArticleId IdType="pmc">PMC9906401</ArticleId><ArticleId IdType="pubmed">32220112</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi C., Wang C., Wang H., Yang C., Cai F., Zeng F., Cheng F., Liu Y., Zhou T., Deng B., et al. Clinical observation of low molecular weight heparin in relieving inflammation in COVID-19 patients: A retrospective cohort study. Clin. Transl. Sci. 2020;13:1087&#x2013;1095. doi: 10.1111/cts.12880.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cts.12880</ArticleId><ArticleId IdType="pmc">PMC7719364</ArticleId><ArticleId IdType="pubmed">32881340</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin S., Huang M., Li D., Tang N. Difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2. J. Thromb. Thrombolysis. 2020;51:1107&#x2013;1110. doi: 10.1007/s11239-020-02105-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11239-020-02105-8</ArticleId><ArticleId IdType="pmc">PMC7124128</ArticleId><ArticleId IdType="pubmed">32246317</ArticleId></ArticleIdList></Reference><Reference><Citation>Spronk H.M., Cate H.T. The blood coagulation system as a molecular machine. BioEssays. 2003;25:1220&#x2013;1228. doi: 10.1002/bies.10360.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/bies.10360</ArticleId><ArticleId IdType="pubmed">14635257</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackman N., Tilley R.E., Key N.S. Role of the Extrinsic Pathway of Blood Coagulation in Hemostasis and Thrombosis. Arter. Thromb. Vasc. Biol. 2007;27:1687&#x2013;1693. doi: 10.1161/ATVBAHA.107.141911.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/ATVBAHA.107.141911</ArticleId><ArticleId IdType="pubmed">17556654</ArticleId></ArticleIdList></Reference><Reference><Citation>Monroe D.M., Hoffman M. What does it take to make the perfect clot? Arter. Thromb. Vasc. Biol. 2006;26:41&#x2013;48. doi: 10.1161/01.ATV.0000193624.28251.83.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.ATV.0000193624.28251.83</ArticleId><ArticleId IdType="pubmed">16254201</ArticleId></ArticleIdList></Reference><Reference><Citation>Heuberger D.M., Schuepbach R.A. Protease-activated receptors (PARs): Mechanisms of action and potential therapeutic modulators in PAR-driven inflammatory diseases. Thromb. J. 2019;17:1&#x2013;24. doi: 10.1186/s12959-019-0194-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12959-019-0194-8</ArticleId><ArticleId IdType="pmc">PMC6440139</ArticleId><ArticleId IdType="pubmed">30976204</ArticleId></ArticleIdList></Reference><Reference><Citation>Posma J.J., Grover S., Hisada Y., Owens A.P., Antoniak S., Spronk H.M., Mackman N. Roles of Coagulation Proteases and PARs (Protease-Activated Receptors) in Mouse Models of Inflammatory Diseases. Arter. Thromb. Vasc. Biol. 2019;39:13&#x2013;24. doi: 10.1161/ATVBAHA.118.311655.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/ATVBAHA.118.311655</ArticleId><ArticleId IdType="pmc">PMC6310042</ArticleId><ArticleId IdType="pubmed">30580574</ArticleId></ArticleIdList></Reference><Reference><Citation>Geisbert T.W., Hensley L.E., Jahrling P.B., Larsen T., Geisbert J.B., Paragas J., Young H.A., Fredeking T., Rote W.E., Vlasuk G.P. Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: A study in rhesus monkeys. Lancet. 2003;362:1953&#x2013;1958. doi: 10.1016/S0140-6736(03)15012-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(03)15012-X</ArticleId><ArticleId IdType="pubmed">14683653</ArticleId></ArticleIdList></Reference><Reference><Citation>Antoniak S., Mackman N. Multiple roles of the coagulation protease cascade during virus infection. Blood. 2014;123:2605&#x2013;2613. doi: 10.1182/blood-2013-09-526277.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2013-09-526277</ArticleId><ArticleId IdType="pmc">PMC3999750</ArticleId><ArticleId IdType="pubmed">24632711</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xea; V.B., Riteau B., Alessi M.-C., Couture C., Jandrot-Perrus M., Rh&#xe9;aume C., Hamelin M., Boivin G. Protease-activated receptor 1 inhibition protects mice against thrombin-dependent respiratory syncytial virus and human metapneumovirus infections. Br. J. Pharmacol. 2017;175:388&#x2013;403. doi: 10.1111/bph.14084.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bph.14084</ArticleId><ArticleId IdType="pmc">PMC5758388</ArticleId><ArticleId IdType="pubmed">29105740</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellinghaus P., Perzborn E., Hauenschild P., Gerdes C., Heitmeier S., Visser M., Summer H., Laux V. Expression of pro-inflammatory genes in human endothelial cell: Compar-ison of rivaroxaban and dabigatran. Thromb. Res. 2016;142:44&#x2013;51. doi: 10.1016/j.thromres.2016.04.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2016.04.008</ArticleId><ArticleId IdType="pubmed">27131284</ArticleId></ArticleIdList></Reference><Reference><Citation>Subbe C., Kruger M., Rutherford P., Gemmel L. Validation of a modified Early Warning Score in medical admissions. Qjm: Int. J. Med. 2001;94:521&#x2013;526. doi: 10.1093/qjmed/94.10.521.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/qjmed/94.10.521</ArticleId><ArticleId IdType="pubmed">11588210</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu F., Zhang Q., Huang C., Shi C., Wang L., Shi N., Fang C., Shan F., Mei X., Shi J., et al. CT quantification of pneumonia lesions in early days predicts progression to severe illness in a cohort of COVID-19 patients. Theranostics. 2020;10:5613&#x2013;5622. doi: 10.7150/thno.45985.</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/thno.45985</ArticleId><ArticleId IdType="pmc">PMC7196293</ArticleId><ArticleId IdType="pubmed">32373235</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor F.B., Jr., Toh C.H., Hoots W.K., Wada H., Levi M. Scientific Subcommittee on Disseminated Intravascular Coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH). Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb. Haemost. 2001;86:1327&#x2013;1330. doi: 10.1055/s-0037-1616068.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0037-1616068</ArticleId><ArticleId IdType="pubmed">11816725</ArticleId></ArticleIdList></Reference><Reference><Citation>Spyropoulos A.C., Ageno W., Albers G.W., Elliott C.G., Halperin J.L., Hiatt W.R., Maynard G.A., Steg P.G., Weitz J.I., Lu W., et al. Post-Discharge Prophylaxis with Rivaroxaban Reduces Fatal and Major Thromboembolic Events in Medically Ill Patients. J. Am. Coll. Cardiol. 2020;75:3140&#x2013;3147. doi: 10.1016/j.jacc.2020.04.071.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2020.04.071</ArticleId><ArticleId IdType="pmc">PMC7308003</ArticleId><ArticleId IdType="pubmed">32586587</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayoubkhani D., Khunti K., Nafilyan V., Maddox T., Humberstone B., Diamond I., Banerjee A. Post-COVID syndrome in individuals admitted to hospital with COVID-19: Retrospective cohort study. BMJ. 2021;372:n693. doi: 10.1136/bmj.n693.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n693</ArticleId><ArticleId IdType="pmc">PMC8010267</ArticleId><ArticleId IdType="pubmed">33789877</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah W., Hillman T., Playford E.D., Hishmeh L. Managing the long term effects of COVID-19: Summary of NICE, SIGN, and RCGP rapid guideline. BMJ. 2021;372:n136. doi: 10.1136/bmj.n136.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n136</ArticleId><ArticleId IdType="pubmed">33483331</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandal S., Barnett J., Brill S.E., Brow n J.S., Denneny E.K., Hare S.S., Heightman M., Hillman T.E., Jacob J., Jarvis H.C., et al. &#x2018;Long-COVID&#x2019;: A cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalisation for COVID-19. Thorax. 2020;76:396&#x2013;398. doi: 10.1136/thoraxjnl-2020-215818.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/thoraxjnl-2020-215818</ArticleId><ArticleId IdType="pmc">PMC7615158</ArticleId><ArticleId IdType="pubmed">33172844</ArticleId></ArticleIdList></Reference><Reference><Citation>Townsend L., Fogarty H., Dyer A., Martin-Loeches I., Bannan C., Nadarajan P., Bergin C., Farrelly C.O., Conlon N., Bourke N.M., et al. Prolonged elevation of D-dimer levels in convalescent COVID-19 patients is independent of the acute phase response. J. Thromb. Haemost. 2021;19:1064&#x2013;1070. doi: 10.1111/jth.15267.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.15267</ArticleId><ArticleId IdType="pmc">PMC8013297</ArticleId><ArticleId IdType="pubmed">33587810</ArticleId></ArticleIdList></Reference><Reference><Citation>De Terwangne C., Laouni J., Jouffe L., Lechien J., Bouillon V., Place S., Capulzini L., Machayekhi S., Ceccarelli A., Saussez S., et al. Predictive Accuracy of COVID-19 World Health Organization (WHO) Severity Classification and Comparison with a Bayesian-Method-Based Severity Score (EPI-SCORE) Pathogens. 2020;9:880. doi: 10.3390/pathogens9110880.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/pathogens9110880</ArticleId><ArticleId IdType="pmc">PMC7692702</ArticleId><ArticleId IdType="pubmed">33114416</ArticleId></ArticleIdList></Reference><Reference><Citation>Klok F.A., Boon G.J., Barco S., Endres M., Geelhoed J.M., Knauss S., Rezek S.A., Spruit M.A., Vehreschild J., Siegerink B. The Post-COVID-19 Functional Status scale: A tool to measure functional status over time after COVID-19. Eur. Respir. J. 2020;56:2001494. doi: 10.1183/13993003.01494-2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.01494-2020</ArticleId><ArticleId IdType="pmc">PMC7236834</ArticleId><ArticleId IdType="pubmed">32398306</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrade B.S., Siqueira S., Soares W.D.A., Rangel F.D.S., Santos N., Freitas A.D.S., da Silveira P.R., Tiwari S., Alzahrani K., G&#xf3;es-Neto A., et al. Long-COVID and Post-COVID Health Complications: An Up-to-Date Review on Clinical Conditions and Their Possible Molecular Mechanisms. Viruses. 2021;13:700. doi: 10.3390/v13040700.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13040700</ArticleId><ArticleId IdType="pmc">PMC8072585</ArticleId><ArticleId IdType="pubmed">33919537</ArticleId></ArticleIdList></Reference><Reference><Citation>Mcmurray J., Packer M., Desai A.S., Gong J., Lefkowitz M.P., Rizkala A.R., Rouleau J.L., Shi V.C., Solomon S.D., Swedberg K., et al. Angiotensin&#x2013;Neprilysin Inhibition versus Enalapril in Heart Failure. N. Engl. J. Med. 2014;371:993&#x2013;1004. doi: 10.1056/NEJMoa1409077.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1409077</ArticleId><ArticleId IdType="pubmed">25176015</ArticleId></ArticleIdList></Reference><Reference><Citation>Acanfora D., Ciccone M.M., Scicchitano P., Acanfora C., Casucci G. Neprilysin inhibitor&#x2013;angiotensin II receptor blocker combination (sacubitril/valsartan): Rationale for adoption in SARS-CoV-2 patients. Eur. Hear. J.&#x2014;Cardiovasc. Pharmacother. 2020;6:135&#x2013;136. doi: 10.1093/ehjcvp/pvaa028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ehjcvp/pvaa028</ArticleId><ArticleId IdType="pmc">PMC7184416</ArticleId><ArticleId IdType="pubmed">32282032</ArticleId></ArticleIdList></Reference><Reference><Citation>Eikelboom J.W., Connolly S.J., Bosch J., Dagenais G.R., Hart R.G., Shestakovska O., Diaz R., Alings M., Lonn E.M., Anand S.S., et al. Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. N. Engl. J. Med. 2017;377:1319&#x2013;1330. doi: 10.1056/NEJMoa1709118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1709118</ArticleId><ArticleId IdType="pubmed">28844192</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi S., Qin M., Shen B., Cai Y., Liu T., Yang F., Gong W., Liu X., Liang J., Zhao Q., et al. Association of Cardiac Injury with Mortality in Hospitalized Patients with COVID-19 in Wuhan, China. JAMA Cardiol. 2020;5:802. doi: 10.1001/jamacardio.2020.0950.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamacardio.2020.0950</ArticleId><ArticleId IdType="pmc">PMC7097841</ArticleId><ArticleId IdType="pubmed">32211816</ArticleId></ArticleIdList></Reference><Reference><Citation>Cate H.T. Surviving COVID-19 with Heparin? N. Engl. J. Med. 2021;385:845&#x2013;846. doi: 10.1056/NEJMe2111151.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMe2111151</ArticleId><ArticleId IdType="pmc">PMC8362589</ArticleId><ArticleId IdType="pubmed">34347948</ArticleId></ArticleIdList></Reference><Reference><Citation>ATTACC Investigators. ACTIV-4a Investigators. REMAP-CAP Investigators Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with COVID-19. N. Engl. J. Med. 2021;385:790&#x2013;802. doi: 10.1056/NEJMoa2105911.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2105911</ArticleId><ArticleId IdType="pmc">PMC8362594</ArticleId><ArticleId IdType="pubmed">34351721</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>